Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Medtronic (MDT) To Report Q4 Earnings: Will It Top Estimates?

By Zacks Investment ResearchStock MarketsMay 20, 2019 09:07PM ET
www.investing.com/analysis/medtronic-mdt-to-report-q4-earnings-will-it-top-estimates-200423518
Medtronic (MDT) To Report Q4 Earnings: Will It Top Estimates?
By Zacks Investment Research   |  May 20, 2019 09:07PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Medtronic plc (NYSE:MDT) is scheduled to report fourth-quarter and fiscal 2019 results on May 23, before the opening bell.

In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 4.03%. In fact, the bottom-line outpaced estimates in the trailing four quarters, the average being 4.84%.

Let’s see how things are shaping up prior to this announcement.

Key Catalysts

We are upbeat about Medtronic’s successful execution of growth strategies such as therapy innovation, globalization and increase in economic value. Combined with the demographics of an aging population, these positives opened up opportunities for the company, which should get reflected in the fiscal fourth-quarter results.

The therapy innovation space has been seeing multiple developments. Under Cardiac and Vascular Group ("CVG"), new therapies are helping the company gain traction in the rapidly growing MedTech market for left ventricular assist device, transcatheter aortic valve replacement, drug-coated balloons, atrial fibrillation ablation and insertable diagnostics.

There has been a consistent and gradually stabilizing trend in the global cardiac rhythm and heart failure ("CRHF") market. The company is expected to register strong growth in its ICD (implantable cardioverter defibrillator) and CRT (cardiac resynchronization therapy) product lines within the scope of CRHF, banking on product launch and creation of meaningful markets.

Strong demand for the company's suite of quadripolar cardiac resynchronization therapy-pacemakers has been driving Heart Failure division revenues.

However, in the fourth quarter, this growth can be offset by a decline in sales of left ventricular assist device (LVAD) as a result of market share loss (due to the regulatory approval of Abbott’s competitive product HeartMate 3) and certain unfavorable changes in heart transplant guideline.

In the to-be-reported quarter, Medtronic is expected to have maintained a decent market share in the core pacing banking on the back of continued uptake of Micra Transcatheter Pacing System and the Azure next generation family of pacemakers.

Within Coronary & Structural Heart, the company is expected to gain from solid demand for CoreValve Evolut PRO globally.

Moreover, the Aortic, Peripheral & Venous division is expected to gain from strength in IN.PACT Admiral drug-coated balloon, Valiant Navion thoracic stent graft and solid growth in VenaSeal closure system. Notably, Medtronic has been continuously seeing strong demand for the IN.PACT Admiral drug-coated balloon in Japan since its commercial launch last August.

Overall, the Zacks Consensus Estimate for CVG revenues in the fiscal fourth quarter is pegged at $3.09 billion, indicating 1.6% drop from the year-ago number.

Within Restorative Therapies Group ("RTG"), the company is again projected to register robust progress, particularly in Brain & Pain divisions, despite challenges in the Spine market.

Medtronic’s integrated robotics and navigation platform Mazor X Stealth is expected to drive growth in Neurosurgery business along with creating demand for core spine implants.

The Zacks Consensus Estimate for RTG revenues in the fiscal fourth quarter is pegged at $2.15 billion, implying 7.5% improvement from the last reported quarter.

Within Minimally Invasive Therapies Group ("MITG"), the company is once again expected to deliver robust performance banking on strong sales of portable hemodialysis system as well as the next generation capsule endoscopy product called PillCam Genius.

The Zacks Consensus Estimate for MITG revenues in the fiscal fourth quarter is pegged at $2.24 billion, suggesting 5.6% improvement from the last reported quarter.

Within Diabetes, Medtronic is likely to have sustained U.S. patient demand for its MiniMed 670G hybrid closed loop system. Outside the United States, the company is witnessing strong demand for 640G system. The company is continuing with the launch of MiniMed 670G in some European countries. This should continue to boost international diabetes revenues. However, difficult year-over-year comparisons in U.S. pump sales may dent growth in the to-be-reported quarter.

The Zacks Consensus Estimate for fourth-quarter Diabetes revenues stands at $634 million, indicating an increase of1.7% from the prior-year reported figure.

Here’s What the Quantitative Model Predicts

Our proven Zacks model shows that a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has high chances of beating estimates if it also has a positive Earnings ESP.

Medtronic has an Earnings ESP of +0.07%. It carries a Zacks Rank #3, which increases the predictive power of ESP. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

The Zacks Consensus Estimate for earnings per share of $1.46 indicates an increase of 2.8% from the year-ago period reported figure.

Other Stocks Worth a Look

Here are a few other stocks that have the right combination of elements to post an earnings beat in their upcoming quarterly results.

Canopy Growth Corporation (NYSE:CGC) has an Earnings ESP of +19.91% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

HEXO Corp. (TO:HEXO) has an Earnings ESP of +14.29% and a Zacks Rank #3.

Centene Corporation (NYSE:CNC) has an Earnings ESP of +0.29% and a Zacks Rank #3.

Will you retire a millionaire?

One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”

Click to get it free >>



Medtronic PLC (MDT): Free Stock Analysis Report

Centene Corporation (CNC): Free Stock Analysis Report

HEXO Corp. (HEXO): Free Stock Analysis Report

Canopy Growth Corporation (CGC): Free Stock Analysis Report

Original post
Medtronic (MDT) To Report Q4 Earnings: Will It Top Estimates?
 

Related Articles

Medtronic (MDT) To Report Q4 Earnings: Will It Top Estimates?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email